Summer 2026

Biology Research Intern

Ipsc

Updated on 7/22/2026

Sartorius

Sartorius

1,001-5,000 employees

Bioprocess and laboratory solutions provider

No salary listed

Ann Arbor, MI, USA

In Person

On-site at Ann Arbor, Michigan; remote not offered.

Category
Biology & Biotech (1)
Required Skills
Data Analysis

Get referred to Sartorius

Find people who can refer or advise you

Requirements
  • MS, PhD or enrolled in a PhD program in Bioengineering, Biology, Chemistry, or closely related discipline
  • Experience in cell culture, with a preference for 3D culture
  • Prior experience with ipsc differentiation and characterization
  • Experience in systematic experimentation and troubleshooting in a laboratory setting
  • Proven ability to collaborate effectively in team environments, with leadership experience in academic and professional settings
  • Identification with our core values: Sustainability, Openness, Enjoyment
Responsibilities
  • Regularly and systematically design and execute experiments, analyze data, and report results
  • Gather and analyze data, perform cell studies using various optical modalities, and report the findings
  • Collaborate effectively with cross-functional teams to support R&D efforts and integration of optical solutions
  • Collaborate with internal subject matter experts to understand applications of emerging technologies
  • Contribute to design and validation of analytical tools
Desired Qualifications
  • Hands-on experience with advanced optical analytical tools such as Light Sheet, Confocal, Raman, or Multiphoton Fluorescence

Sartorius provides laboratory and bioprocessing equipment and services for the biopharmaceutical industry. Its two divisions, Bioprocess Solutions and Lab Products & Services, supply systems, consumables, and analytics used in biotech drug and vaccine development and production. It differentiates itself with a long history, an integrated portfolio, global support, and acquisitions like BioOutsource to offer end-to-end solutions. Its goal is to help biopharmaceutical companies develop and manufacture biotech products more reliably and at scale.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Göttingen, Germany

Founded

1870

Get referred to Sartorius

Find people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Q4 2025 revenue grew 7.6% to over €3.5 billion.
  • The Eveo platform targets CAR-T costs down 90% and output quadrupled.
  • MatTek adds $20 million-plus sales and 3D microtissue models for preclinical workflows.

What critics are saying

  • Lab Products and Services grew just 0.2% in Q4 2025.
  • The €650 million bond matures in autumn 2026 after the new €500 million placement.
  • Eveo's 2027 deliveries leave validation risk unresolved until customer orders begin.

What makes Sartorius unique

  • Founded in 1870, Sartorius built precision balances before bioprocessing.
  • Bioprocess Solutions leads with filtration, fermentation, cell culture, and fluid management.
  • The 2007 Stedim merger created a global single-use bioprocessing platform.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

401(k) Retirement Plan

401(k) Company Match

Paid Vacation

Paid Sick Leave

Paid Holidays

Flexible Work Hours

Wellness Program

Professional Development Budget

Company News

Sartorius AG
May 6th, 2026
Sartorius completes placement of bond with a volume of 500 million euros

May 6, 2026 – Sartorius has successfully issued a bond with a volume of 500 million euros via its Dutch subsidiary Sartorius Finance B.V.. The issue was targeted at institutional investors and met with strong demand, being more than 4 times oversubscribed.

The Associated Press
Mar 16th, 2026
Sartorius launches platform to cut CAR-T manufacturing costs by 90% and quadruple output

Sartorius has launched the Eveo Cell Therapy Platform, an integrated system for producing autologous cell therapies including CAR-T treatments. The modular platform can increase output up to fourfold in existing cleanroom space whilst reducing manufacturing costs by approximately 90 percent. The system integrates cell selection, activation, gene modification, expansion and final formulation into a closed system. Its compact design allows a single operator to process eight patient batches simultaneously in the space traditionally needed for two, potentially producing over 350 doses annually compared to today's 100 doses in the same footprint. A successful pilot with CDMO ElevateBio validated the platform's real-world applicability. Sartorius will begin taking orders in September 2026, with first deliveries expected in 2027.

Yahoo Finance
Feb 3rd, 2026
Sartorius Stedim Biotech posts 18% profit growth despite equipment softness, cuts debt ratio to 3.55

Sartorius Stedim Biotech reported strong profit growth for Q4 2025, with revenue increasing 7.6% in constant currencies to over €3.5 billion. The EBITDA margin improved 170 basis points to 29.7%, whilst underlying net profit surged 18%. The bioprocess solutions division led growth at 9.5% in constant currency, driven by double-digit growth in recurring revenue that offset continued equipment softness. Order intake grew faster than sales, with the book-to-bill ratio remaining above one. Free cash flow reached €390 million, though operating cash flow declined to €837 million from €976 million previously. The net debt-to-EBITDA ratio improved from 3.96 to 3.55 times. However, the company faces headwinds from a weaker US dollar and set broad 2026 guidance due to market volatility.

Yahoo Finance
Feb 3rd, 2026
Sartorius grows revenue 7.6% to €3.5B with EBITDA margin expanding to 29.7%

Sartorius AG reported strong Q4 2025 results, with revenue growing 7.6% in constant currencies to over €3.5 billion, exceeding full-year guidance. The company's EBITDA margin expanded 170 basis points to 29.7%, whilst underlying net profit increased 18%. The bioprocess solutions division drove growth with 9.5% revenue increase in constant currency, supported by strong double-digit growth in recurring revenue. However, the lab products and services division remained essentially flat at 0.2% growth, facing challenges from unfavorable product mix. Sartorius improved its net debt to EBITDA ratio from 3.96 times to 3.55 times, demonstrating financial discipline. The company set a broad guidance range for 2026, citing macroeconomic volatility. Management noted that US onshoring initiatives are expected to impact revenue from 2027 onwards rather than 2026.

Firmenpresse
Sep 16th, 2025
Repairon secures funding for heart therapy

Repairon GmbH, a German biotech company, has secured a substantial Series A funding for its innovative "heart patch" therapy aimed at treating advanced heart failure. The funding, led by Bioventure Management GmbH and co-invested by Satorius AG, will support the Phase 3 trial and GMP production scaling. The heart patch, made from engineered heart muscle, is applied to damaged heart tissue to restore function. Positive preclinical and Phase 1/2 results were published in Nature.